Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial

M. S. Walma, S. J. Rombouts, L. J. H. Brada, I. H. Borel Rinkes, K. Bosscha, R. C. Bruijnen, O. R. Busch, G. J. Creemers, F. Daams, R. M. van Dam, O. M. van Delden, S. Festen, P. Ghorbani, D. J. de Groot, J. W. B. de Groot, N. Haj Mohammad, R. van Hillegersberg, I. H. de Hingh, M. D'Hondt, E. D. KerverM. S. van Leeuwen, M. S. Liem, K. P. van Lienden, M. Los, V. E. de Meijer, M. R. Meijerink, L. J. Mekenkamp, C. Y. Nio, I. Oulad Abdennabi, E. Pando, G. A. Patijn, M. B. Polee, J. F. Pruijt, G. Roeyen, J. A. Ropela, M. W. J. Stommel, J. de Vos-Geelen, J. J. de Vries, E. M. van der Waal, F. J. Wessels, J. W. Wilmink, H. C. van Santvoort, M. G. Besselink, I. Q. Molenaar, Dutch Pancreatic Canc Grp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number313
Number of pages12
JournalTrials
Volume22
Issue number1
DOIs
Publication statusPublished - 29 Apr 2021

Keywords

  • Locally advanced pancreatic cancer
  • Radiofrequency ablation
  • Chemotherapy
  • Overall survival
  • INTERNATIONAL STUDY-GROUP
  • CLINICAL-OUTCOMES
  • PHASE-III
  • GEMCITABINE
  • DEFINITION
  • SURVIVAL
  • ADENOCARCINOMA
  • FOLFIRINOX
  • SURGERY
  • TUMORS

Cite this